WO2015097034A1 - Inhalateur à poudre sèche à dose unique - Google Patents

Inhalateur à poudre sèche à dose unique Download PDF

Info

Publication number
WO2015097034A1
WO2015097034A1 PCT/EP2014/078217 EP2014078217W WO2015097034A1 WO 2015097034 A1 WO2015097034 A1 WO 2015097034A1 EP 2014078217 W EP2014078217 W EP 2014078217W WO 2015097034 A1 WO2015097034 A1 WO 2015097034A1
Authority
WO
WIPO (PCT)
Prior art keywords
dry powder
strip
container
inhaler
powder drug
Prior art date
Application number
PCT/EP2014/078217
Other languages
English (en)
Inventor
Johan Lundgren
Lars Arvidsson
Mårten RITTFELDT
Orest Lastow
Carl Forslund
Original Assignee
Iconovo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconovo Ab filed Critical Iconovo Ab
Publication of WO2015097034A1 publication Critical patent/WO2015097034A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the inhaler comprises at least one air inlet and at least one air outlet, and a container comprising a pre-filled dry powder drug, the inhaler having an airflow there through from the at least one air inlet to the at least one outlet during inhalation by a user at said at least one outlet, which airflow will convey said dry powder drug if inhalation by the user is performed after dispersing said dry powder drug from the container.
  • inhalers In the pharmaceutical field, with respect to treatment of respiratory and/or other diseases, inhalers have been widely used. Numerous drugs, medications and other substances are inhaled into the lungs for rapid absorption in the blood stream and for local action in the lung with such inhalers.
  • Inhaled drugs fall into two main categories, in form of liquids, including suspensions, and powders.
  • the choice of category depends on the characteristics of the drugs, medications, etc., to be inhaled.
  • inhaler The most common type of inhaler is the pressurized metered-dose inhaler.
  • inhaler medication is most commonly stored in solution in a pressurized canister that contains a propellant, although it may also be a suspension.
  • the canister is attached to a plastic, hand-operated actuator. On activation, the metered-dose inhaler releases a fixed dose of medication in aerosol form.
  • nebulizer Another kind of inhaler is a nebulizer, which supply medication as an aerosol created from an aqueous formulation.
  • the kind referred to herein is yet another type, in form of a dry powder inhaler, and specifically a one dose dry powder inhaler.
  • a dry powder inhaler releases a metered or device-metered dose of powdered medication that is inhaled through the inhaler.
  • Dry powder inhalers need to deliver a particle size that is predominantly below
  • WO2008008021 relates to an inhalation system for the administration of a drug in the form of dry powder by inhalation through an airflow path.
  • the system comprises a delivery device, having a mouthpiece through which the powder is inhaled, a dose cassette comprising at least one drug cavity for each dose, comprising a dose to be delivered.
  • WO2010024759 relates to a an inhaler.
  • the inhaler comprises a base having at least one foil sealed cavity containing medicament.
  • a separating element is attached to the foil for separating the foil from the cavity.
  • WO2010021589 relates to an inhaler in which an outlet cover is connected to a movable actuator portion located upstream of a sealed medicament-containing cavity. As the outlet cover is removed from the outlet, the actuator portion moves downstream of the cavity and a sealing foil becomes separated from the cavity.
  • One dose dry powder inhalers are provided with one metered dose, and this kind of inhaler may for example be used for vaccinations, clinical trials or emergency healthcare, wherein the user not is a day to day user, and the inhaler therefore goes to waste after its only use.
  • These kind of inhalers are, for economical reasons, kept to the minimum with regard to pieces and parts, since the consumption is high and lifetime is low. Therefore, they are normally provided with unprotected inlets/outlets, and perhaps with a cover cap applied over, for example, the outlet. In use, such as in emergencies, the user needs to remove the cap, if there is one, and thereafter reveal the drug.
  • a dry powder drug inhaler comprising: a housing, said housing comprising at least one air inlet and at least one air outlet, and a container comprising a dry powder drug, wherein, upon inhalation by a user at said at least one outlet, an airflow from the at least one air inlet to the at least one outlet will convey said dry powder drug if inhalation by the user is performed after dispersing said dry powder drug from the container; and a strip, said strip forming a part of said container and occluding at least one of said at least one air outlet, such that removal of the strip from the housing reveals said dry powder drug and said at least one of said at least one air outlet.
  • Fig. 1 is a perspective view from an outlet end of an inhaler according to an embodiment of the present invention
  • Fig. 2 is a perspective view from an inlet end of an inhaler according to an embodiment of the present invention
  • Fig. 3 is a top view of an inhaler according to an embodiment of the present invention.
  • Fig. 4 is a cross sectional view along a longitudinal axis of an inhaler according to an embodiment of the present invention
  • Fig. 5 is a side and close up view of a container in an inhaler according to an embodiment of the present invention
  • Fig. 6 is a cross sectional view along a longitudinal axis of an inhaler according to an embodiment of the present invention.
  • Fig. 7 is a cross sectional view along a longitudinal axis of an inhaler according to an embodiment of the present invention.
  • Figs. 1 to 5 illustrate a dry powder drug inhaler 100.
  • the dry powder drug inhaler 100 comprises a housing 101.
  • the housing 101 comprises an air inlet 102 and an air outlet 103.
  • the outlet 103 is arranged at a first end of the housing 101, while the inlet 102 is arranged at an opposite second end of the housing 101.
  • the number of inlets may for example be adjusted in accordance with needs and specific inhaler design, such that a number of smaller inlets, for reducing pressure fall over the inhaler, are arranged circumferentially of the housing 101. This is not shown. In a corresponding manner the number of air outlets may be adjusted in accordance with needs and specific inhaler design.
  • the housing 101 may be manufactured in a suitable material, such as injection moldable plastics, such as thermoplastics.
  • the inhaler 100 further comprises a container 104, arranged in the housing 101.
  • the container 104 comprises a dry powder drug, such as in the form of a pre-filled drug containing container 104.
  • a dry powder drug such as in the form of a pre-filled drug containing container 104.
  • the container 104 is preferably arranged close to the first end of the housing 101 , i.e. close to the inlet 102.
  • the drug may be affected directly of air entering the housing 101, such that the drug will have an increased amount of time to be distributed in the air stream before exiting the inhaler 100 at the outlet 103. This results in an improved drug/air profile, increasing the possibility of drug entering an increased area/volume of the lungs of the user.
  • a strip 105 is arranged on the housing 101.
  • the strip 105 forms a part of the container 104, such that removal of the strip 105 will reveal the drug in the container 104.
  • the strip 105 occludes the outlet 103, such that removal of the strip 105 from the housing 101 reveals the outlet 103.
  • the strip 105 forms a protective sheet at the outlet 103, such that the potential user will have a decreased risk of clogging the outlet or getting the outlet 103 dirty during keeping or storage, bearing in mind that the user shall inhale on this outlet 103 during use.
  • the strip 105 closes the container 104, and extends from the container 104 to the outlet 103 to occlude the latter.
  • the strip 105 then closes the container 104 via a first interaction surface between the strip 105 and a container cavity 104b, where after the strip 105 extends away from the container 104 to the outlet 103 to occlude the outlet 103 via a second interaction surface between the strip 105 and the outlet 103.
  • the strip 105 also occludes the inlet 102, such that the strip 105 forms a protective sheet also at the inlet 102, such that the potential user will have a decreased risk of clogging also the inlet 102 or get the inlet 102 dirty during keeping or storage.
  • the strip 105 then closes the inlet 102 via a third interaction surface between the strip 105 and the inlet 102.
  • the strip 105 then extends away from the container 104 and/or the outlet 103 to occlude the inlet 102 via said third interaction surface between the strip 105 and the inlet 102.
  • the closure of the container 104 may be obtained in a different plane than the closure of the outlet 103 and/or the inlet 102, minimizing risk of clogging outlets/inlets by medicament kept in the container 104.
  • the strip 105 has a first end 106 in the vicinity of the outlet 103. This first end
  • the strip 106 allows for easy access of the strip 105, by for example providing it with a pull tab 107.
  • the strip runs longitudinally of said housing 101 to said container 104, optionally via the inlet 102.
  • the strip 105 runs on an outer surface of said housing 101 from the outlet 103 to the container 104, optionally via the inlet 102.
  • the strip 105 is arranged double folded at said container 104, such that it attaches to the container 104 centrally. This means that the strip attaches to the container on a side of the container facing away from the second end of the housing 101, i.e. being closer to the center of the housing along a longitudinal axis of the housing 101 and thus the inhaler 100.
  • the strip 105 when pulling the strip away from the housing 101 , the strip 105 will tear the container 104 in a direction from the centre of the housing 101 towards the second end of the housing 101. Then, the tearing, i.e. the breakage, of the container 104 will reveal the dry powder drug.
  • the container comprises the form of a blister package, wherein the strip 105 attaches to/forms a part of the container 104.
  • the container 104 comprises a base portion 104a, with the cavity 104b for receiving the drug.
  • the container 104 comprises a cover 104c arranged over the container cavity 104b and the drug, and the cover 104c is a part of, i.e. attaches to or is monolithically formed with, the strip 105.
  • the strip 107 and the container 104 may for example be manufactured in a suitable material for enclosing openings and cavities, and specifically cavities for holding moisture sensitive drugs.
  • a suitable material is an aluminum foil, such as an aluminum foil laminated with a plastic. It is not necessary that also the strip 107 is made of a moisture barrier of this kind, but for facilitating manufacturing the same foil may be used for the strip 107 as for the container 104.
  • the user Before use, the user will hence grab the pull tab 107; pull the strip 105 over the outlet 103; then proceed with turning the inhaler 100 or pulling the strip 105 from below also over the inlet 102; to finally pull the strip 105 away from the housing 101 to break the container 104 and reveal the drug. After this, the user will bring the outlet 103 to his/her mouth, and inhale, such that the drug will disperse into the air stream and be conveyed by the air stream into the respiratory tract of the user.
  • the strip 605 runs within the housing 601 of the inhaler 600.
  • the pull tab 607 is positioned at the second end of the housing 601, i.e. in the vicinity of the inlet 602.
  • the strip 605 then also has its first end 606 in said position, where after the strip continues to occlude the inlet 602, then occluding the outlet 603, to finally attach to the container 604.
  • the user will hence grab the pull tab 607; pull the strip 605 out of the inlet 602; then proceed with pulling the tab 607 and the strip away from the inhaler 600 to reveal the outlet 603 from within; continuing pulling the tab 607 and the strip 605 away from the inhaler 600 to break the container 604 and reveal the drug.
  • the user will bring the outlet 603 to his/her mouth, and inhale, such that the drug will spread in the air stream and be conveyed by the air stream into the respiratory tract of the user.
  • This embodiment allows for revealing of the inlet 602, the outlet 603, and the drug in a one directed motion, which may be beneficial if the user for example has a decreased dexterity.
  • the pull tab 707 is again positioned at the second end of the inhaler 700.
  • the strip 705 continues from the pull tab in a bifurcation; one part of the strip continuing over the container 704, to attach thereto centrally of the housing 701; and another part of the strip 705 continuing to occlude the inlet 702, further along the outside of the housing 701 to the first end to there occlude the outlet 703.
  • the user will hence grab the pull tab 707; pull the strip 705 out of the inlet 702; then proceed with pulling the tab 707 and the strip away from the inhaler 700 to break the container 704 to reveal the drug; then proceed with turning the inhaler 700 or pulling the strip 705 from below also over the outlet 703.
  • the user will bring the outlet 703 to his/her mouth, and inhale, such that the drug will spread in the air stream and be conveyed by the air stream into the respiratory tract of the user.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un inhalateur de médicament à poudre sèche (100, 600, 700) comprenant : un boîtier (101, 601, 701), ledit boîtier comprenant au moins une entrée d'air (102, 602, 702) et au moins une sortie d'air (103, 603, 703). L'inhalateur comprend en outre un récipient (104, 604, 704) comprenant un médicament à poudre sèche ; lors de l'inhalation par un utilisateur au niveau de ladite sortie, un flux d'air de ladite entrée d'air à ladite sortie transportant ledit médicament à poudre sèche si l'aspiration de l'utilisateur est réalisée après libération dudit médicament à poudre sèche du récipient. Une bande (105, 605, 705), ladite bande formant une partie dudit récipient et bloquant ladite sortie d'air, est disposée sur ledit boîtier de telle sorte que le retrait de la bande du boîtier libère ledit médicament à poudre sèche et ladite sortie d'air.
PCT/EP2014/078217 2013-12-23 2014-12-17 Inhalateur à poudre sèche à dose unique WO2015097034A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1351577A SE538667C2 (sv) 2013-12-23 2013-12-23 Enkeldostorrpulverinhalator
SE1351577-0 2013-12-23

Publications (1)

Publication Number Publication Date
WO2015097034A1 true WO2015097034A1 (fr) 2015-07-02

Family

ID=52273115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/078217 WO2015097034A1 (fr) 2013-12-23 2014-12-17 Inhalateur à poudre sèche à dose unique

Country Status (2)

Country Link
SE (1) SE538667C2 (fr)
WO (1) WO2015097034A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193379A1 (fr) 2015-06-03 2016-12-08 Iconovo Ab Inhalateur de poudre sèche à dose unique
US20170119982A1 (en) * 2014-05-02 2017-05-04 Manta Devices, Llc Delivery device and related methods
WO2019059826A1 (fr) * 2017-09-19 2019-03-28 Iconovo Ab Inhalateur de poudre sèche comprenant un boîtier ayant une première partie de boîtier et une seconde partie de boîtier
US10456537B2 (en) 2017-03-28 2019-10-29 Concentrx Pharmaceuticals, Inc. Devices and methods for delivering dry powder medicaments
US11426532B2 (en) 2015-06-30 2022-08-30 Greiner Bio-One Gmbh Needle guard with dual hinge functionality

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404454A1 (fr) * 1989-06-21 1990-12-27 FISONS plc Dispositif à utilisation unique pour l'inhalation de médicaments
US5042472A (en) * 1990-10-15 1991-08-27 Merck & Co., Inc. Powder inhaler device
WO1998034662A1 (fr) * 1997-02-07 1998-08-13 Astra Aktiebolag (Publ) Inhalateur a dose unique ii
WO1998034661A1 (fr) * 1997-02-07 1998-08-13 Astra Aktiebolag (Publ) Inhalateur i a dose unique
WO2003103563A2 (fr) * 2002-06-07 2003-12-18 Sun Pharmaceutical Industries Limited Inhalateur de poudre
WO2004004922A1 (fr) * 2002-07-09 2004-01-15 Optinose As Dispositifs de distribution
EP1488819A1 (fr) * 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Inhalateur de poudre sèche et procédé d'inhalation pulmonaire de poudre sèche
WO2007042822A2 (fr) * 2005-10-12 2007-04-19 Innovata Biomed Limited Inhalateur de poudre seche a dose unitaire
WO2013036881A2 (fr) * 2011-09-07 2013-03-14 Syphase, Llc Dispositif d'inhalation de poudre sèche

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404454A1 (fr) * 1989-06-21 1990-12-27 FISONS plc Dispositif à utilisation unique pour l'inhalation de médicaments
US5042472A (en) * 1990-10-15 1991-08-27 Merck & Co., Inc. Powder inhaler device
WO1998034662A1 (fr) * 1997-02-07 1998-08-13 Astra Aktiebolag (Publ) Inhalateur a dose unique ii
WO1998034661A1 (fr) * 1997-02-07 1998-08-13 Astra Aktiebolag (Publ) Inhalateur i a dose unique
WO2003103563A2 (fr) * 2002-06-07 2003-12-18 Sun Pharmaceutical Industries Limited Inhalateur de poudre
WO2004004922A1 (fr) * 2002-07-09 2004-01-15 Optinose As Dispositifs de distribution
EP1488819A1 (fr) * 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Inhalateur de poudre sèche et procédé d'inhalation pulmonaire de poudre sèche
WO2007042822A2 (fr) * 2005-10-12 2007-04-19 Innovata Biomed Limited Inhalateur de poudre seche a dose unitaire
WO2013036881A2 (fr) * 2011-09-07 2013-03-14 Syphase, Llc Dispositif d'inhalation de poudre sèche

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170119982A1 (en) * 2014-05-02 2017-05-04 Manta Devices, Llc Delivery device and related methods
US11147936B2 (en) * 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
WO2016193379A1 (fr) 2015-06-03 2016-12-08 Iconovo Ab Inhalateur de poudre sèche à dose unique
CN107921225A (zh) * 2015-06-03 2018-04-17 艾克诺韦公司 单剂量干粉吸入器
US20180169354A1 (en) * 2015-06-03 2018-06-21 Iconovo Ab Single dose dry powder inhaler
US11058832B2 (en) * 2015-06-03 2021-07-13 Iconovo Ab Single dose dry powder inhaler
US11426532B2 (en) 2015-06-30 2022-08-30 Greiner Bio-One Gmbh Needle guard with dual hinge functionality
US10456537B2 (en) 2017-03-28 2019-10-29 Concentrx Pharmaceuticals, Inc. Devices and methods for delivering dry powder medicaments
US11185647B2 (en) 2017-03-28 2021-11-30 Concentrx Pharmaceuticals, Inc. Devices and methods for delivering dry powder medicaments
US11911560B2 (en) 2017-03-28 2024-02-27 Concentrx Pharmaceuticals, Inc. Devices and methods for delivering dry powder medicaments
WO2019059826A1 (fr) * 2017-09-19 2019-03-28 Iconovo Ab Inhalateur de poudre sèche comprenant un boîtier ayant une première partie de boîtier et une seconde partie de boîtier
US11607509B2 (en) * 2017-09-19 2023-03-21 Iconovo Ab Dry powder inhaler comprising a casing with a first casing portion and a second casing portion

Also Published As

Publication number Publication date
SE538667C2 (sv) 2016-10-11
SE1351577A1 (sv) 2015-06-24

Similar Documents

Publication Publication Date Title
JP4921549B2 (ja) ドライ・パウダー吸入器の改善
US20060021616A1 (en) Inhaler
KR101547502B1 (ko) 코를 통한 전달 장치
WO2015097034A1 (fr) Inhalateur à poudre sèche à dose unique
EP2595685B1 (fr) Appareil de type spray nasal
JPH04259471A (ja) 粉末吸入装置
EP3302661B1 (fr) Inhalateur de poudre sèche à dose unique
US9649454B2 (en) Delivery device and related methods
EP3137140B1 (fr) Dispositif d'administration
JP5394440B2 (ja) 吸入器
RU2760856C2 (ru) Однодозовый ингалятор для порошкообразных лекарственных средств
CN106255524B (zh) 用于吸入粉体的吸入装置
BR112019021035A2 (pt) Inalador de pó de uso único de baixo custo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14821138

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14821138

Country of ref document: EP

Kind code of ref document: A1